`571-272-7822
`
`
`
`
`
` Paper 102
` Entered: October 5, 2016
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`
`
`INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
`INNOPHARMA INC., INNOPHARMA LLC,
`MYLAN PHARMACEUTICALS INC., and MYLAN INC.,
`LUPIN LTD., and LUPIN PHARMACEUTICALS, INC.,
`Petitioners,
`
`v.
`
`SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.,
`Patent Owner.
`_______________
`Case IPR2015-00902 (Patent 8,669,290 B2)
`Case IPR2015-00903 (Patent 8,129,431 B2)1
`_______________
`
`
`Before FRANCISCO C. PRATS, ERICA A. FRANKLIN, and
`GRACE KARAFFA OBERMANN, Administrative Patent Judges.
`
`OBERMANN, Administrative Patent Judge.
`
`
`ORDER
`Granting Petitioner InnoPharma’s Motions to Expunge
`37 C.F.R. §§ 42.5(a); 42.56
`
`
`1 IPR2015-01871 has been joined with IPR2015-00903. This Order
`addresses issues common to both cases identified in the caption.
`
`
`
`
`IPR2015-00902 (Patent 8,669,290 B2)
`IPR2015-00903 (Patent 8,129,431 B2)
`
`
`A Final Written Decision was entered in each proceeding on July 28,
`
`2016. Papers 90, 82.2 On September 21, 2016, in each proceeding,
`
`Petitioner InnoPharma filed a Motion to Expunge. Papers 104, 96. This
`
`Order addresses those Motions.
`
`Petitioner InnoPharma seeks to expunge Exhibit 2109 and the
`
`confidential version of Exhibit 2082 filed under seal in each proceeding.
`
`Paper 104, 1; Paper 96, 1. We previously sealed Exhibit 2109 in its entirety
`
`without requiring a public, redacted version of the document. Paper 100, 2–
`
`3; Paper 92, 2–3. The record includes a redacted, public version of
`
`Exhibit 2082.
`
`Petitioner InnoPharma states that Patent Owner does not oppose the
`
`Motions to Expunge. Paper 104, 1; Paper 96, 1. Petitioner InnoPharma also
`
`establishes that the Motions to Expunge will not remove from the public
`
`record any information cited by the Board in the Final Written Decisions.
`
`Paper 104, 4; Paper 96, 4.
`
`Under the circumstances, we are persuaded that granting Petitioner
`
`InnoPharma’s unopposed Motions to Expunge strikes a reasonable balance
`
`between the need to maintain the confidential nature of sealed information
`
`and the public interest in maintaining a complete and understandable public
`
`file history of the patents at issue. Paper 104, 3–4; Paper 96, 3–4.
`
`Accordingly, we grant Petitioner InnoPharma’s Motions to Expunge. As
`
`previously explained, the redacted, public version of Exhibit 2082 will
`
`remain in the record. Paper 104, 4; Paper 96, 4 (indicating that neither
`
`
`2 We sequentially refer to papers filed in IPR2015-00902 and IPR2015-
`00903.
`
`
`
`
`2
`
`
`
`IPR2015-00902 (Patent 8,669,290 B2)
`IPR2015-00903 (Patent 8,129,431 B2)
`
`exhibit sought to be expunged will result in removal from the record of any
`
`information cited or relied upon in a Final Written Decision).
`
`
`
`It is
`
`ORDERED that Petitioner InnoPharma’s Motions to Expunge (Papers
`
`104, 96) are granted;
`
`FURTHER ORDERED that Exhibit 2109 and the confidential version
`
`of Exhibit 2082 shall be expunged in each proceeding.
`
`.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`IPR2015-00902 (Patent 8,669,290 B2)
`IPR2015-00903 (Patent 8,129,431 B2)
`
`PETITIONERS:
`
`Jitendra Malik, Ph.D.
`Lance Soderstrom
`James Abe
`Joseph Janusz
`ALSTON & BIRD LLP
`jitty.malik@alston.com
`lance.soderstrom@alston.com
`james.abe@alston.com
`joe.janusz@alston.com
`
`Deborah Yellin
`Jonathan Lindsay
`Shannon Lentz
`CROWELL & MORING LLP
`dyellin@crowell.com
`jLindsay@Crowell.com
`SLentz@Crowell.com
`
`PATENT OWNER:
`
`Bryan C. Diner
`Justin J. Hasford
`Joshua Goldberg
`FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP
`Bryan.Diner@finnegan.com
`Justin.Hasford@finnegan.com
`joshua.goldberg@finnegan.com
`
`
`
`
`4
`
`